Rules 4.7.3 and 4.10.3 ASX Listing Rules Appendix 4G (current at 17/7/2020) Page 1 99229889.1 Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Name of entity Cambium Bio Limited ABN/ARBN Financial year ended: 13 127 035 358 30...
FY26 Appendix 4G and Corporate Governance Statement
Filed with ASX · · 24 pages · English
Release
Story so far
Earlier from Cambium Bio
- Change in Company Secretary and Communication Person
- Updated Securities Trading Policy
- Quarterly Activities/Appendix 4C Cash Flow Report
- Cambium Bio Raises A$1.0 Million via Placement
- FDA Confirms Single Pivotal Trial Pathway for Elate Ocular
Later from Cambium Bio
- FY26 Appendix 4E and Annual Report
- Proposed issue of securities - CMB
- Notification regarding unquoted securities - CMB
- Update - Proposed issue of securities - CMB
- Change in Substantial Holding
Follow Cambium Bio into a list and get an email when it puts out news.
Follow Cambium Bio